Malvern and Paraytec enter into development and technology licensing agreement

Malvern Panalytical (Malvern Panalytical, UK) and Paraytec Ltd (York, UK) have entered into a development and licensing agreement that will see Paraytec’s ActiPix® technology being added to Malvern Panalytical’s materials characterization portfolio. The agreement will give Malvern Panalytical exclusive rights to further develop, market and sell ActiPix® UV area imaging technology in specific fields of use related to the characterization of complex fluids for applications in biopharmaceuticals, foods and personal care industrial sectors.

Paul Walker, Managing Director of Malvern Panalytical, said, “We are delighted to be adding Paraytec’s innovative UV area imaging technology to our capability. We see it as complementary to our existing technology portfolio and it offers great potential for further developing and enhancing our product range for particle size and viscosity determination.”

Mark Vaux, Paraytec CEO, said, "This is a landmark agreement for our company. To have been selected by Malvern Panalytical is a huge endorsement of our technology. We look forward to working with the team at Malvern Panalytical and to seeing Malvern Panalytical products incorporating our ActiPix® technology being launched in due course.”

Malvern Panalytical is a market leader in measuring performance controlling material properties, including particle size, particle shape, zeta potential, molecular weight, size and conformation, rheological properties and chemical identification. www.malvern.com

Paraytec manufactures and distributes instrumentation for pharmaceutical and biopharmaceutical applications based on its patented ActiPix® technology, a 2-dimensional detection platform for UV-Vis absorbance measurement, using capillaries and flow cells in conjunction with sophisticated optics and active pixel area sensors. www.paraytec.com

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Malvern Panalytical. (2019, April 30). Malvern and Paraytec enter into development and technology licensing agreement. News-Medical. Retrieved on May 26, 2024 from https://www.news-medical.net/news/20110720/Malvern-and-Paraytec-enter-into-development-and-technology-licensing-agreement.aspx.

  • MLA

    Malvern Panalytical. "Malvern and Paraytec enter into development and technology licensing agreement". News-Medical. 26 May 2024. <https://www.news-medical.net/news/20110720/Malvern-and-Paraytec-enter-into-development-and-technology-licensing-agreement.aspx>.

  • Chicago

    Malvern Panalytical. "Malvern and Paraytec enter into development and technology licensing agreement". News-Medical. https://www.news-medical.net/news/20110720/Malvern-and-Paraytec-enter-into-development-and-technology-licensing-agreement.aspx. (accessed May 26, 2024).

  • Harvard

    Malvern Panalytical. 2019. Malvern and Paraytec enter into development and technology licensing agreement. News-Medical, viewed 26 May 2024, https://www.news-medical.net/news/20110720/Malvern-and-Paraytec-enter-into-development-and-technology-licensing-agreement.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pharmaceutical powder characterisation and inhaler testing workshop to include expert presentations